Trial Profile
A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 23 Jan 2024
Price :
$35
*
At a glance
- Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Daratumumab (Primary) ; Tamibarotene (Primary)
- Indications Acute myeloid leukaemia; Myelodysplastic syndromes
- Focus Adverse reactions; Biomarker; Proof of concept; Therapeutic Use
- Sponsors Syros Pharmaceuticals
- 01 Dec 2023 Results assessing the clinical activity and safety of the tamibarotene in combination with azacitidine in the cohort of 28 (Between 22 July 2019 and 4 May 2020) relapsed and refractory acute myeloid leukemia patients with RARA overexpression treated in this study, published in the Leukemia and Lymphoma.
- 15 Jun 2023 Results reporting molecular and clinical features from patients enrolled in this trial presented at the 28th Congress of the European Haematology Association
- 12 Dec 2022 Status changed from active, no longer recruiting to completed as per Syros Pharmaceuticals Media Release